key: cord-0860338-8tb8q2o7
authors: da Cruz Gouveia, Pedro Alves; Cipriano, Ingrid Cardoso; de Melo, Marina Acevedo Zarzar; da Silva, Helena Texeira Araujo; de Oliveira Amorim, Matheus Augusto; de Sá Leitão, Clezio Cordeiro; Guedes, Maria Magalhães Vasconcelos; Takano, Daniela Mayumi; Filgueira, Norma Arteiro; Ferraz, Cláudia Elise
title: Exuberant bullous vasculitis associated with SARS-CoV-2 infection
date: 2021-01-12
journal: IDCases
DOI: 10.1016/j.idcr.2021.e01047
sha: f1fa4c0063aa760213f61624fc9ded6719dd28b9
doc_id: 860338
cord_uid: 8tb8q2o7

We described a case of exuberant cutaneous small-vessel vasculitis in a 27-year-old male with mild CoVID-19 in Brazil. The patient presented painful purpuric papules and vesicobullous lesions with hemorrhagic content located in the larger amount in the lower limbs and, to a lesser extent in the region of the back and upper limbs, saving palms and soles of the feet. Influenza-like syndrome with anosmia and ageusia was reported seven days before the skin lesions. A real-time reverse transcription polymerase chain reaction was positive on a nasopharyngeal swab for SARS-CoV-2. Histopathological study showed leukocytoclastic cutaneous vasculitis affecting small vessels and microthrombi occluding some vessels. The patient presented an improvement in skin lesions by the fifth day of prednisone therapy. This case highlights the importance of the SARS-CoV-2 test in investigating the etiology of cutaneous vasculitis during this pandemic.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 

Pandemic coronavirus disease (CoVID-19) has a 0.25%-3.0% case-fatality risk estimate, mainly due to pneumonia [1]. Despite the severity of respiratory symptoms, other manifestations have also drawn the attention of the scientific community. Several reports have been described of different cutaneous lesions in CoVID-19 cases. The frequency of skin lesions in these patients varies between 1.8% and 20.4% [2] . The major dermatologic morphologies described in CoVID-19 cases were morbilliform, pernio-like, urticaria, macular erythema, vesicle, papulosquamous and retiform purpura [3] . We describe here a case of cutaneous small-vessel vasculitis (CSVV) in a patient affected by CoVID-19.

A 27-year-old previous healthy male presented to internal medicine department with a 7day history of skin lesions and low-grade fever, in addition to pain, hyperemia and major testicular edema. The cutaneous lesions had upward progression, located in the larger amount in the lower limbs and, to a lesser extent in the region of the back and upper limbs, sparing the palms and soles of the feet. He denied having any new medications, insect bites, and family history of autoimmune disorders. Flu-like syndrome with anosmia and ageusia was reported seven days before the skin lesions, during peak cases of CoVID-19 in the state of Pernambuco, Brazil. Treatment had been started in the emergency department with acyclovir and ceftriaxone, with no improvement in injuries.

Dermatological examination showed painful purpuric papules and vesicobullous lesions, strained from 0.3 to 5 cm in diameter with hemorrhagic content, some with central necrosis and erythematous halo (Figures 1-2) . On admission, blood count, kidney function, liver enzymes and coagulation profile were normal. C-reactive protein level (37 mg/L), D-dimer (7540 ng/mL), and serum ferritin were increased. A clinical diagnosis of cutaneous vasculitis was made and a punch biopsy of one palpable purple papule was performed. Prednisone 1 mg/kg/day and prophylactic enoxaparin were initiated.

Vasculitis work-up included negative antinuclear antibodies, antiphospholipid antibodies, rheumatoid factor, antineutrophilic cytoplasmic autoantibody, and cryoglobulins with normal serum complement levels. Herpes simplex, HIV, hepatitis B and C, and VDRL test were also negative. A real-time reverse transcription polymerase chain reaction (rRT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was positive in a nasopharyngeal swab.

The patient improved during hospitalization with significant pain relief, with no more fever and no new lesions on the third day of corticosteroid therapy. He also had a reduction in testicular edema and an improvement in skin lesions by the fifth day of therapy. Histopathological study showed leukocytoclastic cutaneous vasculitis (LCV) affecting small vessels, microthrombi occluding some vessels and absence of IgA, IgG, IgM and C3 on direct immunofluorescence examination (Figures 3-4) . In the context of pandemic CoVID-19, a confirmatory test for such infection and a negative vasculitis investigation, a diagnosis of CSVV secondary to SARS-CoV-2 infection was established. The patient was discharged using prednisone in good clinical condition.

Few cases are described in the literature of CSVV associated with CoVID-19 [4] [5] [6] [7] , including one case of IgA vasculitis [8] . In researching this diagnosis, we performed histopathology with immunofluorescence, but it was negative. Our patient had more extensive and exuberant bullous hemorrhagic eruptions than similar cases published in Italy and Dubai. The Italian patient, however, had a more severe systemic and pulmonary condition and died, while the other patient was asymptomatic respiratory at the beginning of the skin lesions [5, 6] .

Most cases of CSVV emerged in mild cases of CoVID-19 [4, 6, 7] . Authors postulated that, even in these cases, endothelial damage may occur due to an immune response against viral antigen deposition or by an elevation of IL-6 during infection [4] . The "cytokine storm" (an increase in pro-inflammatory cytokines, in particular IL-6) could achieve the skin and activate dermal dendritic cells, lymphocytes and neutrophils, promoting the vasculitis process [2] . The present In summary, we present a case of exuberant bullous CSVV with microvascular thrombosis attributed to mild CoVID-19. We believe that cases of CSVV in undiagnosed patients during this pandemic should be investigated for SARS-CoV-2. 

Case-fatality risk estimates for COVID-19

Clinical and histopathological features and potential pathological mechanisms of skin lesions in COVID-19: review of the literature

The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries

Cutaneous small vessel vasculitis secondary to COVID-19 infection: a case report

An unusual case of bullous haemorrhagic vasculitis in a COVID-19 patient

Widespread cutaneous small vessel vasculitis secondary to COVID-19 infection

Cutaneous small-vessel vasculitis associated with novel 2019 coronavirus SARS-CoV-2 infection (COVID-19)

Covid-19 related IgA vasculitis

Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases